An observational study in Cardiac Arrest, sponsored by Essentia Health. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-20.
Sponsored by Essentia Health · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Heart Arrest with a site in United States — 40 open to participants now, 45 under way, 2 of them phase 3. Heart Arrest · United States.
Among the 171 studies in Heart Arrest with a site in United States, this one is the 32nd largest by planned enrollment of the 54 observational ones that give a count, is one of 14 that started in 2016, is one of 54 observational ones, and was the 77th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →40 of the 171 studies in Heart Arrest with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 1 days–17 yrs
Mayo Clinic · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 0 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 12 · Phase 4 4
First in 2002; this study’s year is marked. 14 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 200 across 376 observational studies indexed under Heart Arrest.
Median enrollment 72 across the 117 interventional studies, 157 across the 54 observational. Of the 114 that completed or were terminated, 50 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 171 have an industry lead sponsor. The 10 most frequent:
Essentia Health is the lead sponsor of 19 studies on the registry; none are open to participants now.
Essentia Health has 1 study filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
17 of the studies in Heart Arrest with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283850Phase 3Carol BernierSurviving PEA in Roanoke (SPEAR) Study | 2027-02 |
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT05893420AgileMD, Inc.A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | 2026-12-31 |
| NCT02664831MaineHealthImmunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS) | 2027-01 |
| NCT07656259Mayo ClinicCOMPARE-VENT Feasibility Pilot Study | 2027-02-28 |
Add all 17 to your calendar (.ics) → With an account.
Among the 171 studies in Heart Arrest with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Method: Single center, prospective, non-randomized, unblinded case series of all patients presenting with a cardiac arrest. The proposed study will collect data on all comatose patients presenting with cardiac arrest. The primary end point is death from any cause at 30 days from admission.
Significance: Develop criteria to guide an invasive strategy for comatose patients presenting with cardiac arrest, and so avoid ineffective or even futile therapy which carry its own significant risks for patients in the future. The criteria, in turn, can serve as the basis for a prospective, randomized trial in the future.
Research Design and Methods:
General Approach: This study is a prospective, non-randomized, unblinded case series of comatose patients presenting with cardiac arrest to either Essentia East (St. Mary's Medical Center or Miller-Dwan Medical Center) or Essentia West (Innovis Health).
Methods and Materials: Patients will be enrolled over a 60-month period by the PI, Sub-I, or study coordinator. The enrollment goal is 100 patients. The study will collect demographic, clinical and outcome data on comatose patients presenting with cardiac arrest only, and does not prescribe any clinical testing or therapies including PCI or hypothermia. All clinical decisions are left to the discretion of the attending providers.
Consent Process: This study will seek a waiver for informed consent as the patients, by study inclusion criteria, will not be able to provide informed consent, and this study uses a minimal risk design. In the spirit of transparency, attempts will be made to inform the patient, patient representative or family when possible of enrollment in the study within 48 hours of enrollment. The patient or appropriate patient representative identified from the EMR will be spoke to in person or by phone by the PI, sub-PI, or study coordinator.21 The patient and/or family will then have the opportunity to decline participation in the study. The conversation will be documented in the medical record by the PI, sub-PI or study coordinator.
Randomization Process: The study is a prospective, non-randomized, unblinded case series. Patient will be followed as a single cohort, and no randomization is required.
Study Endpoints:
Primary Endpoint:
Secondary Endpoints:
Observational and Data Collection:
Demographic and clinical data will be collected by a study investigator or study coordinator within 24 hours of admission. Potential candidates for participation will be identified by the PI, sub-PI, or study coordinator every morning by contacting the attending critical care or cardiology attending physicians every morning. Once identified, the study PI, sub-PI, or study coordinator will begin the chart review for data collection. Diagnostic and therapeutic management is left to the discretion of the attending providers. The protocol mandates no evaluation or therapies outside the usual practice of the attending providers. Baseline Demographic data will include:
Date of birth/Age Gender LVEF prior to admission Presence or absence of coronary artery disease Presence or absence of Comorbidities including COPD, diabetes, renal failure active malignancy, dementia, anemia Presence of congestive Presence of angina and CCS functional class heart failure and prior to admission NYHA functional Ethnicity class prior to admission
Baseline Clinical Variables that will be obtained include:25
Vitals signs on presentation to receiving facility including blood pressure, heart rate, respiratory rate, weight, height Witnessed or unwitnessed arrest Presence or absence of bystander CPR Resuscitation attempted by trained emergency personnel prior arrival at initial facility (receiving or transferring) Initial Rhythm prior to ROSC (for a pulseless arrest, the initial rhythm when the AED is placed) Therapies applied during resuscitation including CPR, defibrillation, medications, intubation Estimated time from initial arrest to initial ROSC Initial electrocardiogram characteristics including presence or absence of ST elevation, rhythm, corrected QT interval, QRS width Initial perfusing rhythm following resuscitation Time from arrival of medical personnel at scene of arrest to arrival at receiving facility. If the patient is brought to the receiving facility by someone other than medical personnel, then time is set to 0. Time to arrival to referral center from receiving facility. If referral center is also the receiving facility, then the time is set to 0. Time to arrival from receiving facility to intensive care unit or cath lab if the cath lab precedes the ICU Time to arrival to cath lab from the receiving facility Presence or absence of significance obstructive lesions and list of involved vessels if patient undergoes coronary angiography during hospitalization PCI performed and vessels treated if patient undergoes PCI during hospitalization Presence of absence of any ST elevation on an electrocardiogram within 24 hours of admission to referral facility Any use of mechanical support within 24 hours of admission to referral facility Any use of therapeutic cooling within 24 hours of admission to referral facility Any use of vasopressor agents within 24 hours of admission to referral facility Admission hemoglobin, creatine, and cardiac troponin, bicarbonate, pH, pO2 Glasgow Coma Score Presence or absence of cardiogenic shock within 24 hours of admission to referral facility Left Ventricular Ejection Fraction determined during the hospitalization and Closest to the time of death or discharge
During the clinical stay, pertinence clinical data will be collected including recurrent cardiac arrests, need for coronary angiography or revascularization more than 24 hours from admission, or implantation of an implantable cardioverter-defibrillator prior to discharge. Other significant clinical events will also be recorded including need for transfusion or other surgeries. A SCAI risk score22 will be calculated from the collected data by a study investigator or coordinator within 24 hours of admission. If the patient dies prior to discharge, the date and cause of death will be noted. Transfer to hospice or referral for comfort care will be recorded. If the patient is discharged alive, a Glasgow-Pittsburgh Cerebral Perfusion Category as a measurement of neurological function at time of discharge will be assessed. Disposition site (home, hospice, skilled nursing facility, or transfer to higher level of care) will be recorded. Thirty day follow-up will be performed by review of the medical record, review of public death records, or phone call as appropriate to assess vital status. If a recorded height or weight is not available within the first 24 hours, then estimations by either the staff caring for the patient or study coordinator may be used. The study will only collect data and will not include interaction with subjects.
Comatose patients presenting with cardiac arrest to the receiving facility within 12 hours of the event
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Comatose patients following arrest of presumed cardiac etiology arriving to receiving facility within 12 hours of event.
Death from any cause
Death from any cause at 30 days from admission
Time frame: 30 days
Plan to share: Undecided
The record gives a start of Apr 2016, a primary completion of May 2020 and a completion of May 2020. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Essentia Health